This project proposes to examine two aspects of myocardial protection, injury, and repair that have not previously been studied in the heart: The first goal is to identify the mechanisms by which the lysophospholipids sphingosine 1-phosphate (S1P) and lysophosphatidic acid (LPA) protect the heart against acute oxidative stress produced by interventions such as ischemia/reperfuson and hypoxia/reoxygenation. S1P and LPA bind to a family of G-protein-coupled receptors (endothelial differentiation gene or Edg receptors) and evoke a variety of cellular responses. Prominent among these is protection against cell death. We hypothesize that S1P and LPA exert cardioprotective effects by transducing signals involving one or more isoforms of protein kinase C (PKC), particularly epsilon PKC. Alternative signals mediated by Gi, PI-3 kinase, Akt, and their downstream effectors will also be studied. We also will test the hypothesis that the end-effectors of these cardioprotective signal transduction mechanisms ultimately reside in the mitochondria, especially Complex I. These studies will make extensive use of a genetically engineered mouse model, the epsilon PKC null mouse. The second goal is to understand the role of the actin-regulatory protein gelsolin, which binds to LPA, in the acute and long-term responses to myocardial injury. These experiments will utilize a second genetically engineered mouse model, the gelsolin null mouse. We hypothesize that this mouse will be highly vulnerable to acute myocardial ischemia and infarction. As gelsolin is a key regulator of mitochondrial function, we expect that the gelsolin null mouse will exhibit profound abnormalities in mitochondrial transmembrane potential, respiratory activity, and Complex I activity. We also expect that this mouse model will exhibit maladaptive left ventricular remodeling and excessive fibrosis after experimental myocardial infarction. We hypothesize that many of these abnormalities can be reversed or prevented by administration of agents such as cytochalasin D, a fungal toxin that depolymerizes actin filaments.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL068738-01A1
Application #
6652375
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
2002-08-01
Project End
2007-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
1
Fiscal Year
2002
Total Cost
$308,662
Indirect Cost
Name
Northern California Institute Research & Education
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94121
Karliner, Joel S (2013) Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 1831:203-12
Kawabori, Masahito; Kacimi, Rachid; Karliner, Joel S et al. (2013) Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets. World J Cardiol 5:75-86
Lovett, David H; Mahimkar, Rajeev; Raffai, Robert L et al. (2013) N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One 8:e68154
Lovett, David H; Mahimkar, Rajeev; Raffai, Robert L et al. (2012) A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 7:e34177
Dahi, Sia; Karliner, Joel S; Sarkar, Rajabrata et al. (2011) Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia. Int J Exp Pathol 92:50-6
Vessey, Donald A; Li, Luyi; Jin, Zhu-Qiu et al. (2011) A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to ischemic preconditioning. Oxid Med Cell Longev 2011:961059
Kotlyar, Alexander B; Randazzo, Antonio; Honbo, Norman et al. (2010) Cardioprotective activity of a novel and potent competitive inhibitor of lactate dehydrogenase. FEBS Lett 584:159-65
Wang, Guan-Ying; Yeh, Che-Chung; Jensen, Brian C et al. (2010) Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol 298:H913-20
Chatterjee, Kanu; Zhang, Jianqing; Honbo, Norman et al. (2010) Doxorubicin cardiomyopathy. Cardiology 115:155-62
Tao, Rong; Hoover, Holly E; Honbo, Norman et al. (2010) High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 298:H1022-8

Showing the most recent 10 out of 56 publications